Fanconi Anemia: H1 2018 Pipeline Review Covering Abeona Therapeutics, Genethon and Novartis - ResearchAndMarkets.com

DUBLIN--()--The "Fanconi Anemia - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Fanconi Anemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fanconi Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fanconi Anemia and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.

Companies Mentioned

  • Abeona Therapeutics Inc
  • Genethon SA
  • Novartis AG

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Fanconi Anemia - Overview
  4. Fanconi Anemia - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Fanconi Anemia - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Fanconi Anemia - Companies Involved in Therapeutics Development
  16. Abeona Therapeutics Inc
  17. Genethon SA
  18. Novartis AG
  19. Fanconi Anemia - Drug Profiles
  20. ABO-301 - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. eltrombopag olamine - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. EXG-34217 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. Fancalen - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. JP4-039 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. RPL-101 - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. RPL-102 - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. Small Molecules for Fanconi Anemia - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. Stem Cell Therapy 1 for Fanconi Anemia - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. Stem Cell Therapy to Activate FANC-A for Fanconi Anemia - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. Stem Cell Therapy to Activate FANCA for Fanconi Anemia - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. Stem Cell Therapy to Activate FANCA Protein for Fanconi Anemia - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. Fanconi Anemia - Dormant Projects
  69. Fanconi Anemia - Product Development Milestones
  70. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/9vq533/fanconi_anemia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs